EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bioengineered gut bacterium synthesizing levodopa alleviates motor deficits in models of Parkinson’s disease

Piyush Padhi, Ahmed Abdalla, Benjamin Schneider, Nick Backes, Alyssa A Otto, Ileia J Scheibe, Jacob P Thomas, Gargi Khadse, Manikandan Samidurai, Alexander K Jochmans, Amanda George, Gary Zenitsky und 8 weitere

Cell Host & Microbe · 2025-11 · 33 (11) · 1837-1854.e13

DOI: 10.1016/j.chom.2025.10.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Host & Microbe, 2025-11. Verfasst von Piyush Padhi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Isakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA; Department of Physiology and Pharmacology, College of…. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease, Escherichia coli, Gastrointestinal Microbiome. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

L-3,4-Dihydroxyphenylalanine (L-DOPA), synthesized from L-tyrosine, is a direct precursor to dopamine. L-DOPA is the gold-standard treatment for Parkinson's disease (PD), given orally alongside decarboxylase inhibitors (e.g., benserazide) to enhance bioavailability. However, its chronic daily pulsatile-like delivery is associated with complications. Herein, we show the construction and in vivo efficacy of a programmable, titratable, genetically engineered E. coli Nissle 1917 system (EcNL-DOPA) that continuously synthesizes L-DOPA from L-tyrosine for systemic distribution. Oral administration of EcNL-DOPA with benserazide maintains therapeutic plasma L-DOPA concentrations and increases brain dopamine levels. EcNL-DOPA improves motor performance and limits depressive-like behaviors without adverse side effects in healthy mice, Parkinsonian mice, and canine models. Simulated physiological models from pharmacokinetic and pharmacodynamic studies in canines demonstrate the translational feasibility of this biotherapeutic system for potential human studies. This work lays the groundwork for EcNL-DOPA as a continuous, non-invasive microbial drug delivery platform for PD and chronic neurological diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaParkinson DiseaseEscherichia coliGastrointestinal MicrobiomeAntiparkinson AgentsAnimalsMiceDisease Models, AnimalDogsTyrosineBenserazideHumansDopamineBrainAdministration, Oral

Stichwörter der Autor:innen

Canine modelE. coli Nissle 1917MitoParkParkinson’s diseasebacterial therapeuticsdrug deliveryengineered live biotherapeuticsgut microbiomelevodopasynthetic biology

Substanzen

LevodopaTyrosineAntiparkinson AgentsBenserazideDopamine

Autor:innen und Institutionen

  • Isakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA; Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
  • Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
  • Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
  • Isakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA.
  • Isakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
  • Department of Statistics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA 30602, USA.

Förderung

  • NINDS NIH HHS
  • NIA NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging

Zitieren

APA

Padhi, P., Abdalla, A., Schneider, B., Backes, N., Otto, A. A., Scheibe, I. J., Thomas, J. P., Khadse, G., Samidurai, M., Jochmans, A. K., George, A., Zenitsky, G., Jin, H., Anantharam, V., Kanthasamy, A., Mishra, A., Allenspach, K., Mochel, J., Phillips, G. J., & Kanthasamy, A. G. (2025). Bioengineered gut bacterium synthesizing levodopa alleviates motor deficits in models of Parkinson’s disease. Cell Host & Microbe, 33(11), 1837-1854.e13. https://doi.org/10.1016/j.chom.2025.10.005

Vancouver

Padhi P, Abdalla A, Schneider B, Backes N, Otto AA, Scheibe IJ, et al. Bioengineered gut bacterium synthesizing levodopa alleviates motor deficits in models of Parkinson’s disease. Cell Host & Microbe. 2025;33(11):1837-1854.e13. doi:10.1016/j.chom.2025.10.005

BibTeX
@article{Padhi2025,
  author = {Padhi, Piyush and Abdalla, Ahmed and Schneider, Benjamin and Backes, Nick and Otto, Alyssa A and Scheibe, Ileia J and Thomas, Jacob P and Khadse, Gargi and Samidurai, Manikandan and Jochmans, Alexander K and George, Amanda and Zenitsky, Gary and Jin, Huajun and Anantharam, Vellareddy and Kanthasamy, Arthi and Mishra, Aditya and Allenspach, Karin and Mochel, Jonathan and Phillips, Gregory J and Kanthasamy, Anumantha G},
  title = {Bioengineered gut bacterium synthesizing levodopa alleviates motor deficits in models of Parkinson’s disease},
  journal = {Cell Host & Microbe},
  year = {2025},
  volume = {33},
  number = {11},
  pages = {1837--1854.e13},
  doi = {10.1016/j.chom.2025.10.005}
}
Kostenlos starten →